MARIANNA KOSS: Open Payments
NPI 1902993561 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,822 in 59 payments from 16 companies in 2025. Trend: 2023 $2,042 · 2024 $1,522 · 2025 $1,822
Food & beverage: $1,722Education: $100
| Company | Payments | Amount |
|---|---|---|
| Verona Pharma, Inc. | 10 | $291 |
| Actelion Pharmaceuticals US, Inc. | 5 | $214 |
| SCPHARMACEUTICALS INC. | 3 | $182 |
| Novartis Pharmaceuticals Corporation | 6 | $169 |
| Merck Sharp & Dohme LLC | 7 | $156 |
| BIOTRONIK INC. | 1 | $145 |
| Esperion Therapeutics, Inc. | 5 | $124 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $115 |
| Edwards Lifesciences Corporation | 3 | $90 |
| HEARTFLOW, INC. | 4 | $88 |
Products named: Ohtuvayre, OPSUMIT, FUROSCIX, LEQVIO, VERQUVO, AMVIA EDGE, NEXLETOL, SAPIEN 3 Ultra RESILIA.
Industry payments across NY — which companies pay providers there.
